Nasdaq
$0.4311▼ 4.81%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $17.7MShares out 41.1M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
9- 10.13After-hours26.10.14 05:308-KKey event#●●●
BeyondSpring Inc.
BeyondSpring Inc. announced the results of its 2026 annual meeting of shareholders held on October 13, 2026. A total of 20,905,921 shares, representing approximately 50.84% of the 41,119,820 outstanding shares, were represented, and shareholders ratified the appointment of CBIZ CPAs P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2026.…more
$0.4311-4.81%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.6After-hours26.10.07 05:308-KKey event
BeyondSpring Inc.
BeyondSpring Inc. completed the sale of its interests in BeyondSpring Ltd. and SEED Therapeutics Inc. on September 30, 2026. The company received no cash consideration, instead obtaining rights to clinical data from the DUBLIN-4 trial and a commitment from the investor to fund the trial's conduct. The company filed unaudited pro forma financial information reflecting an estimated gain on the disposition of approximately $53.68 million.…more
$0.4311-4.81%vs prev closeView filingShare - 10.2After-hours26.10.03 05:308-KKey event
BeyondSpring Inc.
BeyondSpring Inc. received a notification from Nasdaq stating that it no longer complies with the market value of listed securities (MVLS) requirement, as it fell below $35 million for 30 consecutive business days. The company has until March 29, 2027, to regain compliance, during which time its securities will continue to trade on Nasdaq.…more
$0.4311-4.81%vs prev closeView filingShare
8 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 9.29Pre-market26.09.29 20:01#●●●#●●●#●●●
BeyondSpring Receives FDA Fast Track for Plinabulin and Secures Clinical Funding…more
BeyondSpring's Plinabulin has been granted FDA Fast Track designation for non-small cell lung cancer, while a strategic divestiture of its Chinese subsidiary aims to fund the global Phase 3 trial. These developments improve the company's clinical development path, though the success of the drug remains subject to future trial results.…more
$0.4311-4.81%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 8.14After-hours26.08.15 06:15
●●●●●●●● ●●●●● ●●●●●●
BeyondSpring announced its second-quarter financial results alongside updates on the clinical progress of its lead asset, Plinabulin. The company is prioritizing the initiation of its confirmatory Phase 3 DUBLIN-4 study following a recent leadership transition.…more
$0.4311-4.81%vs prev close
1 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report